About Cobra Biologics
Cobra Biologics is a Healthcare company based in Keele (United Kingdom) founded in 1992, and was acquired by Flerie in October 2021. Biologics development and manufacturing services are provided contractually. The company has 111 employees. Cobra Biologics offers products and services including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its legal entity is COBRA BIOLOGICS LIMITED.
Company details
Cobra Biologics provides contract development and manufacturing solutions to the global life sciences industry covering monoclonal antibodies, recombinant proteins, DNA, viruses, API, cell line derived products for clinical trials and others. Cobra has three GMP approved facilities in Sweden and UK. Cobras drug development services begin from cell line and process development and right until fill and finish and supply for investigational medicinal products and commercial production. The company also offers lyophilisation and fill-finish services for small molecules. Cobra offering includes protein characterization (including peptide mapping, disulphide bridge analysis etc.) bioassay development (cell-based and enzymatic bioassays to quantify the potency of biomolecules) and analytical services. Cobra has proprietary technologies such as Maximum Protein Expression (that uses Ubiquitous Chromatin Opening Elements (UCOEs) technology) to rapidly produce proteins and MAbs from mammalian cells, Automated Bioreactor (from TAP Biosystems) for microbial cell line development and process optimisation, A PEGylation platform through their partnership with QuiaPEG Pharmaceuticals, and an Antibiotic-free Maintenance System called ORT (Operator-Repressor Titration) for producing plasmid DNA without antibiotics, antibiotic resistance genes, with applications in DNA Vaccines, Gene therapy and recombinant protein production.
- Headquarters Keele, United Kingdom
- Employees 111
- Stage Acquired
- SectorsHealthcare
- Website cobrabio.com
- Social LinkedIn X
- Acquired by Flerie (Oct 2021)
- Legal Name Cobra Biologics Limited
- Date of Incorporation 29 Apr, 1992
- Jurisdiction KEELE, STAFFORDSHIRE
Products & Services of Cobra Biologics
Cobra Biologics offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Produces plasmid DNA for advanced therapy applications.
Develops viral vectors for gene and cell therapies.
Provides manufacturing for cell-based therapeutic products.
Packages viral vectors for safe therapy delivery.
Offers custom cloning for genetic therapy research.
Funding Insights of Cobra Biologics
- Total Rounds 3
- Investors Count 1
All 3 funding rounds of Cobra Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Cobra Biologics
Cobra Biologics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Cognate Bioservices and Flerie.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Flerie is engaged in investing in biotech and pharmaceutical companies. | flerie.com | Stockholm, Sweden | ||
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Development and manufacturing services for cell-based therapies are provided. | 2002 | cognatebioservices.com | Hanover, United States |
Investor details for Cobra Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cobra Biologics
8 people are tracked at Cobra Biologics (6 in leadership, 2 in team); the tracked headcount is 111.
| Name | Role | Group |
|---|---|---|
Lee Warren Aca | Finance Director | Leadership |
Sheena Pumford Cipd | HR Director | Leadership |
Peter Coleman | CEO | Leadership |
Mike Austin | VP, Operations | Leadership |
Philip Ridley - Smith | Sales and Marketing Director | Leadership |
Daniel Smith | Chief Scientific Officer | Leadership |
Lars Fahlander | Site Manager, Matfors | Team |
Steve Garland | Site Manager, Keele | Team |
Complete people profiles for Cobra Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cobra Biologics
5 dated milestones of Cobra Biologics across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Cobra Biologics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant,.
- Exit Acquired by Cognate Bioservices.
- Exit Acquired by Flerie.
Web traffic of Cobra Biologics
Websites that share an audience with Cobra Biologics (cobrabio.com).
Websites whose visitors overlap most with Cobra Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| criver.com | 100% | 224.6K | #186,811 | View details | |
cibse.org | cibse.org | 60% | #249,001 | – | |
| sgs.com | 60% | 1.3M | #36,092 | View details |
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Cobra Biologics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cobra Biologics
Complete news archive for Cobra Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cobra Biologics
Cobra Biologics was founded in 1992 and raised its 1st funding round 23 years after it was founded.
Cobra Biologics is headquartered in Keele, United Kingdom. It is registered at Keele, England, United Kingdom.
Cobra Biologics has 111 employees.
Annual revenue of Cobra Biologics is $33.57M as on Dec 25, 2021.
Cobra Biologics provides contract development and manufacturing solutions to the global life sciences industry covering monoclonal antibodies, recombinant proteins, DNA, viruses, API, cell line derived products for clinical trials and others. Cobra has three GMP approved facilities in Sweden and UK. Cobras drug development services begin from cell line and process development and right until fill and finish and supply for investigational medicinal products and commercial production. The company also offers lyophilisation and fill-finish services for small molecules. Cobra offering includes protein characterization (including peptide mapping, disulphide bridge analysis etc.) bioassay development (cell-based and enzymatic bioassays to quantify the potency of biomolecules) and analytical services. Cobra has proprietary technologies such as Maximum Protein Expression (that uses Ubiquitous Chromatin Opening Elements (UCOEs) technology) to rapidly produce proteins and MAbs from mammalian cells, Automated Bioreactor (from TAP Biosystems) for microbial cell line development and process optimisation, A PEGylation platform through their partnership with QuiaPEG Pharmaceuticals, and an Antibiotic-free Maintenance System called ORT (Operator-Repressor Titration) for producing plasmid DNA without antibiotics, antibiotic resistance genes, with applications in DNA Vaccines, Gene therapy and recombinant protein production.
Cobra Biologics offers Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Cobra Biologics has 3 investors. Key investors include Gov.uk, Cognate Bioservices, and Flerie.
Cobra Biologics operates through Cobra Biologics Limited.
Yes. Cobra Biologics was acquired by Flerie in October 2021.